Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Fish and Richardson
Mallinckrodt
Express Scripts
Daiichi Sankyo
Chubb
Deloitte
Cerilliant

Generated: April 22, 2018

DrugPatentWatch Database Preview

OMNIPAQUE 70 Drug Profile

« Back to Dashboard

Which patents cover Omnipaque 70, and what generic alternatives are available?

Omnipaque 70 is a drug marketed by Ge Healthcare and is included in one NDA.

The generic ingredient in OMNIPAQUE 70 is iohexol. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iohexol profile page.
Drug patent expirations by year for OMNIPAQUE 70
Pharmacology for OMNIPAQUE 70
Medical Subject Heading (MeSH) Categories for OMNIPAQUE 70
Synonyms for OMNIPAQUE 70
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
1,3-Benzenedicarboxamide, 5-(acetyl(2,3-dihydroxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
1,3-benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
1,3-Benzenedicarboxamide, 5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-
108I950
5-(N-2-3-DIHYDROXYPROPYL-ACETMIDO)-2,4,6-TRIIODO-N,N'-bis-(2,3-DIHYDROXYPROPYL)-ISOPHTHALAMIDE
5-(N-2,3-Dihydroxypropylacetamido)-2,4,6-triiodo-N,N inverted exclamation marka-bis(2,3-dihydroxypropyl)isophthalamide
5-(N-2,3-Dihydroxypropylacetamido)-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide
5-(N-dhp-acetamido)-2,4,6-triiodo-N,N'-B is-dhp-isophthalami
5-[acetyl(2,3-dihydroxypropyl)amino]-1-N,3-N-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[Acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide
5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-benzene-1,3-dicarboxamide
5-[acetyl(2,3-dihydroxypropyl)amino]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
5-[N-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamide
5-[n-(2,3-Dihydroxypropyl)acetamido]-2,4,6-triiodo-N,N'-bis(2,3-dihydroxypropyl)isophthalamidesolution
66108-95-0
A835339
AB0012347
AC-1934
AC1L1GKZ
AK323623
AKOS015895399
ALBB-028959
AM030198
Ambap66108-95-0
AN-14471
API0003012
AS-12699
BC209326
BCBcMAP01_000051
BPBio1_000511
BRN 2406632
BSPBio_000463
C-23546
C19H26I3N3O9
CAS-66108-95-0
CC-29572
CCG-220512
CHEBI:31709
CHEMBL1200455
CS-2811
CTK8G0334
D01817
D02BLO
DB01362
DR003589
DSSTox_CID_3157
DSSTox_GSID_23157
DSSTox_RID_76895
DTXSID6023157
EBD45459
EC 266-164-2
EINECS 266-164-2
Exypaque
FT-0627276
Histodenz
Histodenz(TM), nonionic density gradient medium
Histodenz™
Histodenz|||Nycodenz
HMS1569H05
HMS2096H05
HMS2235D07
HMS3369O04
HY-B0594
I06-0659
I0903
Imagenil 300
Imagenil 350
Imaginil
iohexol
Iohexol (JP17/USP/INN)
Iohexol [USAN:BAN:INN:JAN]
Iohexol [USAN:USP:INN:BAN:JAN]
Iohexol for peak identification, European Pharmacopoeia (EP) Reference Standard
Iohexol injection (JP17)
Iohexol, analytical standard
Iohexol, European Pharmacopoeia (EP) Reference Standard
Iohexol, United States Pharmacopeia (USP) Reference Standard
Iohexolum
Iohexolum [INN-Latin]
IOX
KS-00001F7T
LS-29715
MFCD00077732
MLS001332585
MLS001332586
MLS002153854
MolPort-003-931-371
N,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
n,n'-bis(2,3-dihydroxypropyl)-5-[n-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodoisophthalamide
N1,N3-bis(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
N1,N3-bis[2,3-bis(oxidanyl)propyl]-5-[2,3-bis(oxidanyl)propyl-ethanoyl-amino]-2,4,6-tris(iodanyl)benzene-1,3-dicarboxamide
NCGC00166000-01
NCGC00166000-02
NCGC00166000-04
NTHXOOBQLCIOLC-UHFFFAOYSA-N
Nycodenz
Omnipaque
Omnipaque (TN)
Omnipaque 180
Omnipaque 210
Omnipaque 240
Oxilan iohexol
Prestwick_802
Prestwick0_000512
Prestwick1_000512
Prestwick2_000512
Prestwick3_000512
SC-17734
SCHEMBL26501
SMP1_000152
SMR000857075
SPBio_002384
SR-01000838892
SR-01000838892-2
Tox21_112286
Tox21_112286_1
WIN 39424
WIN-39424
ZX-AN079772

US Patents and Regulatory Information for OMNIPAQUE 70

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ge Healthcare OMNIPAQUE 70 iohexol SOLUTION;URETHRAL 018956-007 Jun 1, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Express Scripts
McKinsey
Fuji
Daiichi Sankyo
Fish and Richardson
McKesson
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.